Go Pro
→ The Last Gold Bull Market? (From Paradigm Press) (Ad)tc pixel Free PFSA Stock Alerts

Profusa (PFSA) Competitors

Profusa logo
$1.91 +0.11 (+6.11%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.94 +0.04 (+1.83%)
As of 09/18/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PFSA vs. AMIX, ZYXI, BJDX, NXL, and VSA

Should you buy Profusa stock or one of its competitors? Profusa's main competitors and comparable companies include Autonomix Medical (AMIX), Zynex (ZYXI), Bluejay Diagnostics (BJDX), Nexalin Technology (NXL), and TCTM Kids IT Education (VSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Profusa compare to Autonomix Medical?

Profusa (NASDAQ:PFSA) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

9.8% of Profusa shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 15.0% of Profusa shares are held by insiders. Comparatively, 6.2% of Autonomix Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profusa's return on equity of 0.00% beat Autonomix Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
ProfusaN/A N/A -1,731.09%
Autonomix Medical N/A -267.73%-216.75%

Autonomix Medical has a consensus price target of $42.00, suggesting a potential upside of 897.62%. Given Autonomix Medical's stronger consensus rating and higher probable upside, analysts plainly believe Autonomix Medical is more favorable than Profusa.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Profusa
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Autonomix Medical
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Profusa had 4 more articles in the media than Autonomix Medical. MarketBeat recorded 6 mentions for Profusa and 2 mentions for Autonomix Medical. Profusa's average media sentiment score of 0.58 beat Autonomix Medical's score of -0.12 indicating that Profusa is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Profusa
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Autonomix Medical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Profusa has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Autonomix Medical has a beta of -1, suggesting that its share price is 200% less volatile than the broader market.

Autonomix Medical has lower revenue, but higher earnings than Profusa. Autonomix Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Profusa$100K11.65-$35.82M-$5.62 thousandN/A
Autonomix MedicalN/AN/A-$16.72M-$41.57N/A

Summary

Profusa and Autonomix Medical tied by winning 7 of the 14 factors compared between the two stocks.

How does Profusa compare to Zynex?

Zynex (NASDAQ:ZYXI) and Profusa (NASDAQ:PFSA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Zynex has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Profusa has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zynex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Profusa
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Profusa has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Profusa's return on equity of 0.00% beat Zynex's return on equity.

Company Net Margins Return on Equity Return on Assets
Zynex-68.35% -804.30% -36.67%
Profusa N/A N/A -1,731.09%

Zynex has higher revenue and earnings than Profusa. Zynex is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zynex$108.20M0.04$2.99M-$2.43N/A
Profusa$100K11.65-$35.82M-$5.62 thousandN/A

In the previous week, Profusa had 6 more articles in the media than Zynex. MarketBeat recorded 6 mentions for Profusa and 0 mentions for Zynex. Profusa's average media sentiment score of 0.58 beat Zynex's score of 0.00 indicating that Profusa is being referred to more favorably in the news media.

Company Overall Sentiment
Zynex Neutral
Profusa Positive

29.7% of Zynex shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 49.3% of Zynex shares are held by company insiders. Comparatively, 15.0% of Profusa shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Zynex beats Profusa on 7 of the 13 factors compared between the two stocks.

How does Profusa compare to Bluejay Diagnostics?

Profusa (NASDAQ:PFSA) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Profusa's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProfusaN/A N/A -1,731.09%
Bluejay Diagnostics N/A -125.00%-99.79%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Profusa
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Bluejay Diagnostics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

9.8% of Profusa shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 15.0% of Profusa shares are held by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profusa has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

In the previous week, Profusa had 5 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 6 mentions for Profusa and 1 mentions for Bluejay Diagnostics. Profusa's average media sentiment score of 0.58 beat Bluejay Diagnostics' score of -0.35 indicating that Profusa is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Profusa
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bluejay Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bluejay Diagnostics has lower revenue, but higher earnings than Profusa. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Profusa$100K11.65-$35.82M-$5.62 thousandN/A
Bluejay DiagnosticsN/AN/A-$6.85M-$7.11N/A

Summary

Profusa beats Bluejay Diagnostics on 6 of the 11 factors compared between the two stocks.

How does Profusa compare to Nexalin Technology?

Profusa (NASDAQ:PFSA) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Profusa had 6 more articles in the media than Nexalin Technology. MarketBeat recorded 6 mentions for Profusa and 0 mentions for Nexalin Technology. Profusa's average media sentiment score of 0.58 beat Nexalin Technology's score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company Overall Sentiment
Profusa Positive
Nexalin Technology Neutral

Profusa has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.95, meaning that its share price is 295% more volatile than the broader market.

Nexalin Technology has higher revenue and earnings than Profusa. Nexalin Technology is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Profusa$100K11.65-$35.82M-$5.62 thousandN/A
Nexalin Technology$300K11.92-$8.22M-$14.41N/A

9.8% of Profusa shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 15.0% of Profusa shares are owned by company insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profusa has a net margin of 0.00% compared to Nexalin Technology's net margin of -4,141.94%. Profusa's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
ProfusaN/A N/A -1,731.09%
Nexalin Technology -4,141.94%-278.24%-218.42%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Profusa
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nexalin Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Nexalin Technology beats Profusa on 7 of the 13 factors compared between the two stocks.

How does Profusa compare to TCTM Kids IT Education?

Profusa (NASDAQ:PFSA) and TCTM Kids IT Education (NASDAQ:VSA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Profusa
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TCTM Kids IT Education
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
ProfusaN/A N/A -1,731.09%
TCTM Kids IT Education N/A N/A N/A

In the previous week, Profusa had 6 more articles in the media than TCTM Kids IT Education. MarketBeat recorded 6 mentions for Profusa and 0 mentions for TCTM Kids IT Education. Profusa's average media sentiment score of 0.58 beat TCTM Kids IT Education's score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company Overall Sentiment
Profusa Positive
TCTM Kids IT Education Neutral

TCTM Kids IT Education has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than TCTM Kids IT Education, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Profusa$100K11.65-$35.82M-$5.62 thousandN/A
TCTM Kids IT Education$150K18.63$245.80M$45.000.05

Profusa has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, TCTM Kids IT Education has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

9.8% of Profusa shares are held by institutional investors. Comparatively, 49.8% of TCTM Kids IT Education shares are held by institutional investors. 15.0% of Profusa shares are held by insiders. Comparatively, 32.9% of TCTM Kids IT Education shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

TCTM Kids IT Education beats Profusa on 9 of the 11 factors compared between the two stocks.

Get Profusa News Delivered to You Automatically

Sign up to receive the latest news and ratings for PFSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PFSA vs. The Competition

Export
MetricProfusaHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.16M$5.55B$7.24B$13.19B
Dividend YieldN/A1.80%2.57%12.81%
P/E Ratio0.0025.34275.4925.40
Price / Sales11.6572.49646.0189.45
Price / CashN/A32.6476.2551.42
Price / Book0.005.6910.466.33
Net Income-$35.82M$151.55M$3.49B$358.33M
7 Day Performance-21.40%0.66%0.59%1.12%
1 Month Performance-74.77%-3.33%-1.74%-2.39%
1 Year PerformanceN/A6.79%18.13%5.35%

Profusa Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PFSA
Profusa
0.8789 of 5 stars		$1.91
+6.1%		N/AN/A$1.16M$100KN/A2
AMIX
Autonomix Medical
2.4714 of 5 stars		$4.12
-2.1%		$42.00
+919.4%		-81.1%$4.09MN/AN/A1
ZYXI
Zynex
N/A$0.13
flat		N/AN/A$3.80M$108.20MN/A770
BJDX
Bluejay Diagnostics
0.8587 of 5 stars		$0.81
-4.1%		N/A-84.2%$3.79MN/AN/A9
NXL
Nexalin Technology
0.8544 of 5 stars		$4.90
+1.0%		N/A-82.5%$3.56M$300KN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PFSA) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
“Elon’s nightmare” could fund your retirement
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
NVDA CEO says it’s a "once-in-a-generation opportunity"
NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...
Monument Traders Alliance | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel